Speakers 2014
- View more
AGARWAL Kosh
UK
- View more
AGHEMO Alessio
Italy
- View more
ANTY Rodolphe
France
-
State of the art lecture and Award (chairman)
-
How to optimize treatment in G4 patients? (chairman)
Presentation
-
- View more
- View more
BELHADJ BRIK Najet
Tunisia
-
Faut-il traiter les immunotolérants et les porteurs inactifs ? (French speaking luncheon) (chairman)
Presentation
-
- View more
BENHAMOU Yves
France
- View more
-
Optimal therapy of HBeAg-negative chronic hepatitis B (chairman)
Presentation
-
- View more
BOYER Nathalie
France
-
Faut-il traiter les immunotolérants et les porteurs inactifs ? (French speaking luncheon) (chairman)
Presentation
-
-
Traitement des patients rechuteurs et non-répondeurs (French speaking luncheon) (chairman)
Presentation
-
BRUNETTO Maurizia
Italy
-
Clinical applications of HBsAg quantification (chairman)
Presentation
-
- View more
- View more
-
Faut-il traiter les immunotolérants et les porteurs inactifs ? (French speaking luncheon) (chairman)
Presentation
-
- View more
CARDOSO Ana Carolina
Brazil
- View more
-
Clinical applications of HBsAg quantification (chairman)
-
The control of HBV related liver disease (chairman)
Presentation
-
-
First line therapy: interferon or analogues? (chairman)
-
Impact of HBV therapy on the incidence of hepatocellular carcinoma
Presentation
-
-
How to optimize treatment in G1 naive patients? (chairman)
Presentation
-
Staging of fibrosis: liver biopsy or indirect markers? (chairman)
Presentation
-
- View more
- View more
DELFRAISSY Jean-François
France
-
Comment optimiser le traitement des malades naïfs ? (French speaking luncheon) (chairman)
Presentation
-
- View more
DI MARTINO Vincent
France
- View more
-
Special populations (chairman)
Presentation
-
-
Triple therapy with telaprevir or boceprevir: management of side effects (chairman)
Presentation
-
- View more
FLISIAK Robert
Poland
-
Controversy: F1/F2 patients: treat or wait? (chairman)
-
Triple therapy with telaprevir or boceprevir: management of side effects
Presentation
-
-
How to optimize current therapy of non G1 patients (chairman)
Presentation
-
The long term impact of treatment on the outcome of liver disease? (chairman)
-
Optimal therapy of HBeAg-positive chronic hepatitis B (chairman)
Presentation
-
- View more
- View more
-
Traitement des patients rechuteurs et non-répondeurs (French speaking luncheon) (chairman)
Presentation
-
HORBAN Andrzej
Poland
-
How to manage relapsers and non-responders to PEG IFN + RBV therapy? (chairman)
Presentation
-
- View more
-
How to optimize current therapy of G1 patients (chairman)
-
HIV-HCV coinfections (chairman)
Presentation
-
-
Optimal therapy of HBeAg-positive chronic hepatitis B (chairman)
Presentation
-
- View more
- View more
- View more
- View more
-
Staging of fibrosis: liver biopsy or indirect markers? (chairman)
-
Special populations (chairman)
Presentation
-
- View more
LEROY Vincent
France
-
Future therapeutic strategies with direct acting antivirals (chairman)
Presentation
-
- View more
LIM Seng Gee
Singapore
-
Optimal therapy of HBeAg-negative chronic hepatitis B (chairman)
Presentation
-
MANNS Michael
Germany
-
How to optimize current therapy of non G1 patients (chairman)
Presentation
-
-
Introduction: Treatment of hepatitis C: soon the end of the road ?
-
State of the art lecture and Award (chairman)
-
Conclusion
Presentation
-
- View more
MATHURIN Philippe
France
-
Resistance to DAAs: is this a real issue? (chairman)
Presentation
-
-
New therapeutic strategies (chairman)
Presentation
-
-
How to optimize current therapy of G1 patients (chairman)
Presentation
-
OULD GOUGAM Rachid
Algeria
-
Faut-il traiter les immunotolérants et les porteurs inactifs ? (French speaking luncheon)
Presentation
-
- View more
- View more
PAIS Raluca
France
- View more
-
How to manage relapsers and non-responders to PEG IFN + RBV therapy?
Presentation
-
-
Triple therapy with telaprevir or boceprevir: management of side effects (chairman)
Presentation
-
- View more
PETERSEN Jorg
Germany
-
First line therapy: interferon or analogues? (chairman)
Presentation
-
- View more
-
Faut-il traiter les immunotolérants et les porteurs inactifs ? (French speaking luncheon)
Presentation
-
RATZIU Vlad
France
-
How to optimize treatment in G1 naive patients? (chairman)
Presentation
-
-
New therapeutic perspectives (chairman)
Presentation
-
- View more
ROCKSTROH Juergen
Germany
- View more
SALMON Dominique
France
- View more
SAYEGH Raymond
Lebanon
-
Interféron ou analogue ? (French speaking luncheon)
Presentation
-
-
Controversy: F1/F2 patients: treat or wait? (chairman)
Presentation
-
-
Protease, polymerase and NS5A inhibitors: what will be the wining combination?
-
Resistance to DAAs: is this a real issue? (chairman)
Presentation
-
- View more
SERFATY Lawrence
France
- View more
- View more
SOBESKY Rodolphe
France
SOGNI Philippe
France
-
Interféron ou analogue ? (French speaking luncheon) (chairman)
Presentation
-
Presentation
- View more
TRAN Albert
France
- View more
- View more
URBANEK Petr
Czech Republic
VALLA Dominique
France
-
Treatment of HCV cirrhosis and transplanted patients (chairman)
Presentation
-
-
Comment optimiser le traitement des malades naïfs ? (French speaking luncheon) (chairman)
Presentation
-
- View more
- View more
WEILAND Ola
Sweden
- View more
YAZDANPANAH Yazdan
France
-
Interféron ou analogue ? (French speaking luncheon) (chairman)
Presentation
-
ZEUZEM Stefan
Germany
-
The long term impact of treatment on the outcome of liver disease? (chairman)
-
New therapeutic strategies (chairman)
Presentation
-
-
How to manage relapsers and non-responders to PEG IFN + RBV therapy? (chairman)
Presentation
-
ZOULIM Fabien
France
-
The control of HBV related liver disease (chairman)
Presentation
-